XUANWU CLOUD (02392) repurchased 8.351 million shares in the first half of the year under the restricted stock award plan.
Recently, Xuanwu Cloud (02392) released the company's 2024 midterm report.
Recently, XUANWU CLOUD (02392) released its mid-year report for 2024. During the reporting period, the company achieved a revenue of 650 million yuan, a year-on-year increase of 22.2%; at the same time, based on measures such as cost control, the company significantly reduced its net loss in the first half of the year by 69.5% to 6 million yuan. It is worth noting that during the reporting period, XUANWU CLOUD repurchased 8.351 million shares through the restricted stock incentive plan. As of the end of the reporting period, the trust entity of XUANWU CLOUD's restricted stock incentive plan held a total of 16.064 million shares, with 1.407 million shares allocated to employees as incentive shares.
In response to this, the management of XUANWU CLOUD stated at the performance release conference that the company had already announced a buyback plan in the first half of the year. Previously, in order to attract more talent to join the company and incentivize outstanding core employees, the company chose to repurchase shares through a trust to implement employee incentives, in order to better support the construction of an excellent team and the long-term development of the business. In the future, with the implementation of new rules by the Hong Kong Stock Exchange allowing repurchasing of shares for stock inventory, the company will continuously monitor policy and market changes and make corresponding strategic adjustments to the repurchase method as appropriate.
Related Articles

GD-HKGBA HLDGS (01396) issued 310 million shares of preferred stock.

In the first three quarters of this year, the total revenue of PA GOODDOCTOR (01833) was about 3.725 billion yuan, an increase of 13.6% year-on-year. The company will continue to expand AI technology to improve the efficiency and quality of medical services.

Sinopharm (01099): China National Pharmaceutical Group's operating profit in the first three quarters was 962 million yuan, a year-on-year decrease of 10.34%.
GD-HKGBA HLDGS (01396) issued 310 million shares of preferred stock.

In the first three quarters of this year, the total revenue of PA GOODDOCTOR (01833) was about 3.725 billion yuan, an increase of 13.6% year-on-year. The company will continue to expand AI technology to improve the efficiency and quality of medical services.

Sinopharm (01099): China National Pharmaceutical Group's operating profit in the first three quarters was 962 million yuan, a year-on-year decrease of 10.34%.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025